Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.53 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.53 |
| ▸ | ABAT | P80404 | 1/20 | 0.53 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.53 |
| ▸ | FDPS | P14324 | 1/20 | 0.50 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL111326 | 0.89 | ALDH1A1 (0.53) | ALDH1A1TSHRTDP1HPGDTRIM24 | |
| SCHEMBL6294276 | 0.86 | ALDH1A1 (0.59) | ALDH1A1TSHRTDP1HPGDTRIM24 | |
| SCHEMBL13512685 | 0.86 | ALDH1A1 (0.50) | ALDH1A1TSHRTDP1HPGDTRIM24 | |
| SCHEMBL19628274 | 0.86 | ALDH1A1 (0.50) | ALDH1A1TSHRTDP1HPGDTRIM24 | |
| SCHEMBL19317368 | 0.86 | ALDH1A1 (0.51) | ALDH1A1TSHRTDP1HPGDTRIM24 | |
| SCHEMBL16560287 | 0.81 | ALDH1A1 (0.46) | ALDH1A1TSHRTDP1HPGDTRIM24 | |
| SCHEMBL13362398 | 0.81 | ALDH1A1 (0.59) | ALDH1A1TSHRTDP1HPGDTRIM24 | |
| SCHEMBL96635 | 0.81 | ALDH1A1 (0.59) | ALDH1A1TSHRTDP1HPGDTRIM24 | |
| SCHEMBL16619850 | 0.81 | ALDH1A1 (0.59) | ALDH1A1TSHRTDP1HPGDTRIM24 | |
| SCHEMBL13776913 | 0.80 | ALDH1A1 (0.41) | ALDH1A1TSHRTDP1HPGDTRIM24 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4232431-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO INC (US) | 2025-08-13 | — | — | EP | disclosed |
| CN-115268215-B | Photosensitive polyimide resin composition, photosensitive polyimide film containing photosensitive polyimide resin composition and application of photosensitive polyimide film | 吉林奥来德光电材料股份有限公司 | 2025-05-16 | — | — | CN | disclosed |
| US-20240400562-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4419509-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-118339149-A | Compounds and compositions for treating conditions associated with LPA receptor activity | 罗特斯生物公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230285327-A1 | DESOXYSCALINE DERIVATIVES WITH MODIFIED MESCALINE-LIKE ACTION | Mind Medicine, Inc. (US) | 2023-09-14 | — | — | US | disclosed |
| EP-4232431-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-115246930-B | Novel polyimide resin, photosensitive polyimide resin composition, and preparation methods and applications thereof | 吉林奥来德光电材料股份有限公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-1224714-A | N- (4-amidinophenyl) glycinamide derivatives | HOFFMANN LA ROCHE (CH) | 1999-08-04 | — | — | CN | disclosed |
| EP-0921116-A1 | N-(4-carbamimido-phenyl)-glycine amide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-06-09 | — | — | EP | disclosed |
| US-5859067-A | PREPARING BIS(2-HYDROXY-1-NAPHTHYL)DECANE FROM THE CORRESPONDING DIACID; FORMING ACID DICHLORIDE; TREATING WITH 2-NAPHTHOL; REARRANGEMENT; REDUCTION; INHIBITS ACTION OF ADENOSINE TRIPHOSPHATASE | ROUFOGALIS BASIL DON (AU) | 1999-01-12 | — | — | US | disclosed |
| WO-1999000114-A2 | BIOLOGICALLY ACTIVE 1,3-BIS-AROMATIC-PROP-2-EN-1-ONES, 1,3-BIS-AROMATIC-PROPAN-1-ONES, AND 1,3-BIS-AROMATIC-PROP-2-YN-1-ONES | STATENS SERUM INSTITUT (DK) | 1999-01-07 | — | — | WO | disclosed |
| US-5741821-A | PHENOLIC ENZYME INHIBITORS | THE UNIVERSITY OF SYDNEY (AU) | 1998-04-21 | — | — | US | disclosed |
| EP-0703780-A4 | USE OF NATURAL PRODUCTS AND RELATED SYNTHETIC COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | UNIV SYDNEY (AU) | 1998-01-07 | — | — | EP | disclosed |
| CN-1124922-A | Use of natural products and related synthetic compounds for the treatment of cardiovascular diseases | UNIV SYDNEY (AU) | 1996-06-19 | — | — | CN | disclosed |
| EP-0703780-A1 | USE OF NATURAL PRODUCTS AND RELATED SYNTHETIC COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | THE UNIVERSITY OF SYDNEY (AU) | 1996-04-03 | — | — | EP | disclosed |
| WO-1994028886-A1 | USE OF NATURAL PRODUCTS AND RELATED SYNTHETIC COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | THE UNIVERSITY OF SYDNEY (AU) | 1994-12-22 | — | — | WO | disclosed |
| US-4115650-A | Process for preparing 2,4-diamino-5-(substituted benzyl)-pyrimidines | HOFFMANN-LA ROCHE INC. (US) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400562-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LPAR1, LPAR2, LPAR6 | ALDH1A1 1774/4885TSHR 1266/4885TDP1 3095/4885 |
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LPAR1, LPAR2, LPAR5 | ALDH1A1 1641/4885TSHR 925/4885TDP1 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.